Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for food industry professionals · Monday, December 17, 2018 · 471,359,000 Articles · 3+ Million Readers

Pressure BioSciences (OTC.QB: PBIO) Makes Good on its Promise to Promote PCT

/ Pressure BioSciences compares to Agilent Technologies, Inc. (NYSE:A), Life Technologies Corporation (NASDAQ:LIFE) and Thermo Fisher Scientific, Inc. (NYSE:TMO) as they are all leading providers of important sample preparation or analytical mass spectrometry equipment, which is widely used in the analysis of small molecules including proteins, DNA and RNA.

Pressure BioSciences, Inc. , is breaking ground with their barocyclers, microtubes, isolation kits and proprietary Pressure Cycling Technology (PCT) - a platform with more life science applications than any layperson could ever dream of. Currently, the company trades at $0.21 per share with a market cap of $2.24 million. And, anyone who suggests that PBIO is significantly undervalued…is exactly right.

Infectious microorganisms are fairly difficult to pin down even for most of today's state-of-the-art molecular-based diagnostic methods. Headaches inevitably arise as scientists strive for a safe sample preparation of potentially harmful substances while simultaneously trying to preserve the sample's molecular integrity. This is why, with PCT and their Shredder SG3 System, PBIO has virtually no competition. And, now that their product is sufficiently honed and singular, the company aims to shift from development toward sales and marketing. With a recent focus on DNA detection and decontamination, it seems there is no molecule to elusive for PCT.

On the heels of good news about increased DNA detection in forensic samples, not to mention a 70 percent revenue growth for the second consecutive quarter, PBIO has continued to add top level clients, expand their strategic partnerships and widen an overseas distribution network. On November 7, 2012, Cole-Parmer (a worldwide leader in providing equipment and consumables to labs) announced that they had signed a Supplier Agreement, under which it will distribute the PBI Shredder SG3 System and processing tubes on a non-exclusive basis.

The company will also be a focus of the keynote address at the opening ceremony of this year's ClinMicro - a veritable jamboree of biotech bigwigs with a mix of microbiologists, microbial Genomics experts, leading companies and powerful academics from around the world. It was announced on Halloween Day that Dr. Bradford Powell, President of Cernomics Solutions, would present PBIO and PCT in his keynote address and in another main session presentation later in the conference being held at the Hilton San Antonio Airport starting November 12.

Before ClinMicro, Dr. Powell talked up PCT saying, "It has already been demonstrated that the PCT Platform has the ability to inactivate and extract live attenuated virus and bacteria that are used as models of important biological threat agents. To that end, protein and nucleic acid markers from Venezuelan Equine Encephalitis virus and Bacillus anthracis (Sterne) spores were processed in less than an hour, as safely and as effectively as conventional procedures that often require more time, as well as large investments for facilities infrastructure, training, and oversight. Consequently, we are confident that the PCT Platform has the potential to provide an adaptable, cost-effective solution for advancing the capability, safety, and performance of assays used in the clinical and microbial genomics sciences. This is a transformative technology whose time has come for broad application and acceptance."

The possibilities of PCT are almost limitless. The technology could already improve test samples, aid clinical laboratory medicine, and improve healthcare across the globe. Embracing this microbiological advancement means simplifying the job of people who track criminals and catching a potentially harmful virus where we wouldn't have otherwise looked. It means stopping contaminated low-quality food before something like "pink slime" reaches our children's school lunch line. And, these endeavors seem more than worthy of federal funding, scientific sponsorship or some such hefty investment. The FBI already has use for PCT's capabilities, and so does the FDA, the USDA, and the CDC, so it seems only a matter of time before its use becomes widespread. Either way, we'd keep a watchful eye on this fascinating and promising small cap. Perhaps Dr. Nate Lawrence, Vice President of Sales and Marketing of PBI, summed up PBIO's current situation best with this recent comment:

We also believe that these advantages will continue to compel researchers to integrate the PCT Platform into their basic scientific studies and clinical applications, resulting in measurable revenue growth and product visibility for Pressure BioSciences, Inc."

Always read our full disclaimer/disclosure pertaining to this article
Seraphim Strategies
922 Mc Mullen Booth Rd
Clearwater FL 33759
Lou Levenstein

Forward-Looking Statements
Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of its PCT-based product line; changes in customer's needs and technological innovations; the Company's and its strategic partners/distributors sales forces may not be successful in selling the Company's PCT product line because scientists may not perceive the advantages of PCT over other sample preparation methods; that other researchers may not be able to replicate the data reported in the studies mentioned; and if actual operating costs are higher than anticipated, or revenues from product sales are less than anticipated, the Company may need additional capital beyond December 2012. Further, given the uncertainty in the capital markets and the current status of the Company's product development and commercialization activities, Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Powered by EIN Presswire

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release